An improved mouse orthotopic bladder cancer model exhibiting progression and treatment response characteristics of
human recurrent bladder cancer

Naito,Tomoharu; Higuchi,Tamami; Shimada,Yasuhiro; Kakinuma,Chihaya

doi:10.3892/ol.2019.11172

An improved mouse orthotopic bladder cancer model exhibiting progression and treatment response characteristics of human recurrent bladder cancer

Authors:
- Tomoharu Naito
- Tamami Higuchi
- Yasuhiro Shimada
- Chihaya Kakinuma
View Affiliations

Affiliations: Pharmaceutical and Healthcare Research Laboratories, FUJIFILM Corporation, Ashigarakami‑gun, Kanagawa 258‑8577, Japan
Published online on: December 2, 2019 https://doi.org/10.3892/ol.2019.11172
Pages: 833-839
Copyright: © Naito et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nonmuscle‑invasive (superficial) bladder cancer is generally treated via surgical removal, followed by adjuvant therapy (bacillus Calmette‑Guerin). However, bladder cancer can often recur, and in a substantial number of recurrent cases, the cancer progresses and metastasizes. Furthermore, residual microtumors following excision may lead to an increased risk of recurrence. An in vivo model mimicking the pattern of urinary bladder microtumor regrowth may provide an effective experimental system for improving postsurgical treatment outcomes. A mouse bladder cancer model established using orthotopic transplant of UM‑UC‑3 human urinary bladder carcinoma cells has been established, however, to the best of our knowledge, no report has investigated sequential histological changes, including early‑phase changes and treatment responses in bladder cancer. In the present study, the efficiency of the model was optimized and the sequential changes were examined using histopathology and in situ imaging. The therapeutic effects of cisplatin (CDDP) and gemcitabine (GEM) were also examined, which are drugs that are often used for follow‑up chemotherapy. Tumor‑seeding efficiency reached 90‑100%, with muscle layer and bladder lumen invasion occurring in ~21 days, using the following modifications: i) Shallow catheter insertion to mitigate bladder wall damage; ii) bladder pretreatment using prewarmed trypsin, followed by light urethral clamping and body temperature maintenance for more efficient removal of transitional epithelium; and iii) seeding with UM‑UC‑3 cells (rather than HT1376, 5637 or T24 tumor cells) in a medium supplemented with Matrigel. Transplant with UM‑UC‑3 cells resulted in isolated microlesions that progressed into tumors, invading the bladder lumen and muscle layer to the serosal surface. Tumor growth was markedly reduced by weekly intravenous injections of CDDP and partially suppressed by GEM. Therefore, this model is reliable, and pathological progression and treatment responses recapitulate the features of recurrent human bladder cancer.

View Figures

View References

1	Lynch CF and Cohen MB: Urinary system. Cancer. 75:316–329. 1995. View Article : Google Scholar : PubMed/NCBI
2	Barocas DA and Clark PE: Bladder cancer. Curr Opin Oncol. 20:307–314. 2008. View Article : Google Scholar : PubMed/NCBI
3	Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, Kiemeney L, Kriegmair M, Montironi R, Murphy WM, et al: Bladder cancer: Epidemiology, staging and grading, and diagnosis. Urology. 66 (Suppl):S4–S34. 2005. View Article : Google Scholar
4	Jacobs BL, Lee CT and Montie JE: Bladder cancer in 2010: How far have we come? CA Cancer J Clin. 60:244–272. 2010. View Article : Google Scholar : PubMed/NCBI
5	Brawn PN: The origin of invasive carcinoma of the bladder. Cancer. 50:515–519. 1982. View Article : Google Scholar : PubMed/NCBI
6	Kanematsu A, Tsuji Y, Kanba H, Noguchi T, Kamoto T and Okabe T: The sensitivity and clinical implications of periodical bladder biopsy following transurethral resection of superficial bladder transitional cell carcinoma. Hinyokika kiyo. Acta urologica Japonica (Japanese). 47:1–4. 2001.
7	Koss LG, Nakanishi I and Freed SZ: Nonpapillary carcinoma in situ and atypical hyperplasia in cancerous bladders: Further studies of surgically removed bladders by mapping. Urology. 9:442–455. 1977. View Article : Google Scholar : PubMed/NCBI
8	Koss LG, Tiamson EM and Robbins MA: Mapping cancerous and precancerous bladder changes. A study of the urothelium in ten surgically removed bladders. JAMA. 227:281–286. 1974. View Article : Google Scholar : PubMed/NCBI
9	Zincke H, Utz DC and Farrow GM: Review of mayo clinic experience with carcinoma in situ. Urology. 26 (Suppl):S39–S46. 1985.
10	Kamat AM, Flaig TW, Grossman HB, Konety B, Lamm D, O'donnell MA, Uchio E, Efstathiou JA and Taylor III JA: Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nat Rev Urol. 12:225–235. 2015. View Article : Google Scholar : PubMed/NCBI
11	Gasión JP and Cruz JF: Improving efficacy of intravesical chemotherapy. Eur Urol. 50:225–234. 2006. View Article : Google Scholar : PubMed/NCBI
12	Huebner D, Rieger C, Bergmann R, Ullrich M, Meister S, Toma M, Wiedemuth R, Temme A, Novotny V, Wirth MP, et al: An orthotopic xenograft model for high-risk non-muscle invasive bladder cancer in mice: Influence of mouse strain, tumor cell count, dwell time and bladder pretreatment. BMC Cancer. 17:7902017. View Article : Google Scholar : PubMed/NCBI
13	Matsumoto R, Tsuda M, Wang L, Maishi N, Abe T, Kimura T, Tanino M, Nishihara H, Hida K, Ohba Y, et al: Adaptor protein CRK induces epithelial-mesenchymal transition and metastasis of bladder cancer cells through HGF/c-Met feedback loop. Cancer Sci. 106:709–717. 2015. View Article : Google Scholar : PubMed/NCBI
14	van der Horst G, van Asten JJ, Figdor A, van den Hoogen C, Cheung H, Bevers RF, Pelger RC and van der Pluijm G: Real-time cancer cell tracking by bioluminescence in a preclinical model of human bladder cancer growth and metastasis. Eur Urol. 60:337–343. 2011. View Article : Google Scholar : PubMed/NCBI
15	Nogawa M, Yuasa T, Kimura S, Tanaka M, Kuroda J, Sato K, Yokota A, Segawa H, Toda Y, Kageyama S, et al: Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest. 115:978–985. 2005. View Article : Google Scholar : PubMed/NCBI
16	Kim CJ, Tambe Y, Mukaisho KI, Sugihara H, Kageyama S, Kawauchi A and Inoue H: Periostin suppresses in vivo invasiveness via PDK1/Akt/mTOR signaling pathway in a mouse orthotopic model of bladder cancer. Oncol Lett. 13:4276–4284. 2017. View Article : Google Scholar : PubMed/NCBI
17	Chan E, Patel A, Heston W and Larchian W: Mouse orthotopic models for bladder cancer research. BJU Int. 104:1286–1291. 2009. View Article : Google Scholar : PubMed/NCBI
18	Seager C, Puzio-Kuter AM, Cordon-Cardo C, McKiernan J and Abate-Shen C: Mouse models of human bladder cancer as a tool for drug discovery. Curr Protoc Pharmacol. 49:142010. View Article : Google Scholar
19	Zhang N, Li D, Shao J and Wang X: Animal models for bladder cancer: The model establishment and evaluation (Review). Oncol Lett. 9:1515–1519. 2015. View Article : Google Scholar : PubMed/NCBI
20	Kobayashi T, Owczarek TB, McKiernan JM and Abate-Shen C: Modelling bladder cancer in mice: Opportunities and challenges. Nat Rev Cancer. 15:42–54. 2015. View Article : Google Scholar : PubMed/NCBI
21	Shimada K, Nakamura M, Anai S, De Velasco M, Tanaka M, Tsujikawa K, Ouji Y and Konishi N: A novel human AlkB homologue, ALKBH8, contributes to human bladder cancer progression. Cancer Res. 69:3157–3164. 2009. View Article : Google Scholar : PubMed/NCBI
22	Zhou JH, Rosser CJ, Tanaka M, Yang M, Baranov E, Hoffman RM and Benedict WF: Visualizing superficial human bladder cancer cell growth in vivo by green fluorescent protein expression. Cancer Gene Ther. 9:681–686. 2002. View Article : Google Scholar : PubMed/NCBI
23	JoVE Science Education Database. Lab Animal Research. Anesthesia Induction and Maintenance. JoVE; Cambridge, MA: 2019
24	Kameoka S, Matsumoto K, Kai Y, Yonehara Y, Arai Y and Honda K: Establishment of temporomandibular joint puncture technique in rats using in vivo micro-computed tomography (R_mCT(R)). Dentomaxillofac Radiol. 39:441–445. 2010. View Article : Google Scholar : PubMed/NCBI
25	Takahashi R, Yokobori T, Osone K, Tatsuki H, Takada T, Suto T, Yajima R, Kato T, Fujii T, Tsutsumi S, et al: Establishment of a novel method to evaluate peritoneal microdissemination and therapeutic effect using luciferase assay. Cancer Sci. 107:341–346. 2016. View Article : Google Scholar : PubMed/NCBI
26	Higuchi T, Yokobori T, Naito T, Kakinuma C, Hagiwara S, Nishiyama M and Asao T: Investigation into metastatic processes and the therapeutic effects of gemcitabine on human pancreatic cancer using an orthotopic SUIT2 pancreatic cancer mouse model. Oncol Lett. 15:3091–3099. 2017.PubMed/NCBI
27	Dobek GL and Godbey WT: An orthotopic model of murine bladder cancer. J Vis Exp. (pii): 25352011.PubMed/NCBI
28	Sternberg CN, de Mulder PH, Schornagel JH, Theodore C, Fossa SD, Van Oosterom AT, Witjes F, Spina M, Van Groeningen CJ, De Balincourt C, et al: Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol. 19:2638–2646. 2001. View Article : Google Scholar : PubMed/NCBI
29	Ghatalia P, Zibelman M, Geynisman DM and Plimack E: Approved checkpoint inhibitors in bladder cancer: which drug should be used when? Ther Adv Med Oncol. 10:17588359187883102018. View Article : Google Scholar : PubMed/NCBI
30	von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 18:3068–3077. 2000. View Article : Google Scholar : PubMed/NCBI
31	von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A and Arning M: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 23:4602–4608. 2005. View Article : Google Scholar : PubMed/NCBI